JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants

PLoS Pathogens

Volumn 10, Issue 4, 2014, Pages

  Sundqvist, Emilie ^a   Buck, Dorothea ^b   Warnke, Clemens ^a   Albrecht, Eva ^c   Gieger, Christian ^c   Khademi, Mohsen ^a   Lima Bomfim, Izaura ^a   Fogdell Hahn, Anna ^a   Link, Jenny ^a   Alfredsson, Lars ^a   Søndergaard, Helle Bach ^d   Hillert, Jan ^a,u   Barcellos, Lisa ^f   Booth, David ^g   McCauley, Jacob L ^h   Comabella, Manuel ⁱ   Compston, Alastair ^j   DAlfonso, Sandra ^k   De Jager, Philip ^l   Fontaine, Bertrand ^m   Goris, An ⁿ   Hafler, David ^o   Haines, Jonathan ^p   Harbo, Hanne F ^q   Hauser, Stephen L ^r   Hawkins, Clive ^s   Hemmer, Bernhard ^t   Ivinson, Adrian ^v   Kockum, Ingrid ^a   Martin, Roland ^w   Boneschi, Filippo Martinelli ^x   Oksenberg, Jorge ^r   Olsson, Tomas ^a   Oturai, Annette ^y   Patsopoulos, Nikolaos ^l   Pericak Vance, Margaret ^h   Saarela, Janna ^z   Sawcer, Stephen ^j   Spurkland, Anne ^aa   Stewart, Graeme ^g   Zipp, Frauke ^ab   Oturai, Annette B ^d   Hemme, Bernhard ^b,e   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d Rigshospitalet   (Denmark)

^e Germany 3 Munich Cluster for Systems Neurology   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^l HARVARD MEDICAL SCHOOL   (United States)

^m UNIVERSITY OF LEUVEN   (Belgium)

ⁿ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^o YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p VANDERBILT UNIVERSITY   (United States)

^q ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^t TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^u KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^v The Harvard Center for Neurodegeneration & Repair   (United States)

^w UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^x SAN RAFFAELE HOSPITAL   (Italy)

^y UNIVERSITY OF COPENHAGEN   (Denmark)

^z UNIVERSITY OF HELSINKI   (Finland)

^aa UNIVERSITY OF OSLO   (Norway)

^ab UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; VERY LATE ACTIVATION ANTIGEN 4; HLA DQ ANTIGEN; HLA-DQB1 ANTIGEN; HLA-DRB1*15 ANTIGEN;

ADULT; ALLELE; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHROMOSOME 6; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; JC VIRUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OPTICAL DENSITY; POLYMERASE CHAIN REACTION; POLYOMAVIRUS INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; MULTICENTER STUDY; SCANDINAVIA;

ALLELES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HAPLOTYPES; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; JC VIRUS; MALE; POLYOMAVIRUS INFECTIONS; SCANDINAVIAN AND NORDIC COUNTRIES;

EID: 84901344743     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004084     Document Type: Article

References (50)

1. Astrom KE, Mancall EL, Richardson EP Jr, (1958) Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81: 93-111.
2. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH, (1971) Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1: 1257-1260.
3. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, et al. (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10: 816-824.
4. Ermis U, Weis J, Schulz JB, (2013) PML in a patient treated with fumaric acid. N Engl J Med 368: 1657-1658.
5. Piccinni C, Sacripanti C, Poluzzi E, De Ponti F, (2013) Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants. Pharmacoepidemiol Drug Saf 22: 443-445.
6. Schmedt N, Andersohn F, Garbe E, (2012) Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 21: 1216-1220.
7. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP, (2013) PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 368: 1658-1659.
8. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, et al. (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366: 1870-1880.
9. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, et al. (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68: 295-303.
10. Plavina T, Berman M, Njenga M, Crossman M, Lerner M, et al. (2012) Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol 53: 65-71.
11. Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, et al. (2011) Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70: 742-750.
12. Sorensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, et al. (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18: 143-152.
13. Warnke C, Ramanujam R, Plavina T, Bergstrom T, Goelz S, et al. (2013) Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry 84: 1199-205.
14. Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, et al. (2012) Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 78: 1736-1742.
15. Outteryck O, Ongagna JC, Duhamel A, Zephir H, Collongues N, et al. (2012) Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol 259: 2293-2298.
16. Calgua B, Barardi CR, Bofill-Mas S, Rodriguez-Manzano J, Girones R, (2011) Detection and quantitation of infectious human adenoviruses and JC polyomaviruses in water by immunofluorescence assay. J Virol Methods 171: 1-7.
17. Warnke C, Pawlita M, Dehmel T, Posevitz-Fejfar A, Hartung HP, et al. (2013) An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Mult Scler 19: 1137-44.
18. Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, et al. (2013) JC virus antibody status underestimates infection rates. Ann Neurol 74: 84-90.
19. Askar M, Daghstani J, Thomas D, Leahy N, Dunn P, et al. (2013) 16(th) IHIW: global distribution of extended HLA haplotypes. Int J Immunogenet 40: 31-38.
20. Bettens F, Nicoloso de Faveri G, Tiercy JM, (2009) HLA-B51 and haplotypic diversity of B-Cw associations: implications for matching in unrelated hematopoietic stem cell transplantation. Tissue Antigens 73: 316-325.
21. Alper CA, Larsen CE, Dubey DP, Awdeh ZL, Fici DA, et al. (2006) The haplotype structure of the human major histocompatibility complex. Hum Immunol 67: 73-84.
22. Jelcic I, Aly L, Binder TM, Bofill-Mas S, Planas R, et al. (2013) T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol 87: 3393-3408.
23. Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, et al. (2013) JC virus antibody status underestimates infection rates. Ann Neurol 74: 84-90.
24. Major EO, Frohman E, Douek D, (2013) JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med 368: 2240-2241.
25. Whitmire JK, (2011) Induction and function of virus-specific CD4+ T cell responses. Virology 411: 216-228.
26. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A,et al. (2013) JCV Antibody Index Stratifies PML Risk in Natalizumab-Treated MS Patients. In: The 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers. Orlando, Florida, United States. pp. Paper1642.
27. Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, et al. (2011) Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 204: 103-114.
28. Reid CE, Li H, Sur G, Carmillo P, Bushnell S, et al. (2011) Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 204: 237-244.
29. Gheuens S, Fellay J, Goldstein DB, Koralnik IJ, (2010) Role of human leukocyte antigen class I alleles in progressive multifocal leukoencephalopathy. J Neurovirol 16: 41-47.
30. Rubicz R, Yolken R, Drigalenko E, Carless MA, Dyer TD, et al. (2013) A Genome-Wide Integrative Genomic Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1). PLoS Genet 9: e1003147.
31. Cangussu LO, Teixeira R, Campos EF, Rampim GF, Mingoti SA, et al. (2011) HLA class II alleles and chronic hepatitis C virus infection. Scand J Immunol 74: 282-287.
32. Chen D, McKay JD, Clifford G, Gaborieau V, Chabrier A, et al. (2011) Genome-wide association study of HPV seropositivity. Hum Mol Genet 20: 4714-4723.
33. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, et al. (2009) A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 41: 591-595.
34. Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, et al. (2010) New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun 11: 232-238.
35. Png E, Thalamuthu A, Ong RT, Snippe H, Boland GJ, et al. (2011) A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. Hum Mol Genet 20: 3893-3898.
36. Khor CC, Chau TN, Pang J, Davila S, Long HT, et al. (2011) Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet 43: 1139-1141.
37. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007) A whole-genome association study of major determinants for host control of HIV-1. Science 317: 944-947.
38. Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, et al. (2011) Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 43: 455-458.
39. Link J, Kockum I, Lorentzen AR, Lie BA, Celius EG, et al. (2012) Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis. PLoS One 7: e36779.
40. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L, (2009) Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 73: 696-701.
41. Holmen C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, et al. (2011) A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 17: 708-719.
42. Olerup O, Zetterquist H, (1992) HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39: 225-235.
43. Dilthey AT, Moutsianas L, Leslie S, McVean G, (2011) HLA*IMP-an integrated framework for imputing classical HLA alleles from SNP genotypes. Bioinformatics 27: 968-972.
44. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, et al. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
45. Dilthey A, Leslie S, Moutsianas L, Shen J, Cox C, et al. (2013) Multi-Population Classical HLA Type Imputation. PLoS Comput Biol 9: e1002877.
46. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. (2013) Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45: 1353-60.
47. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM, (2007) GenABEL: an R library for genome-wide association analysis. Bioinformatics 23: 1294-1296.
48. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904-909.
49. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
50. R Development Core Team (2008) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.